LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $19 | -100.0% | 13,196 | -72.9% | 0.00% | -71.4% |
| Q3 2022 | $55,000 | -70.6% | 48,628 | -58.9% | 0.01% | -75.0% |
| Q2 2022 | $187,000 | +67.0% | 118,308 | +63.2% | 0.03% | +86.7% |
| Q1 2022 | $112,000 | -40.4% | 72,506 | -9.4% | 0.02% | -51.6% |
| Q1 2021 | $188,000 | +1346.2% | 80,000 | +426.6% | 0.03% | +342.9% |
| Q2 2020 | $13,000 | – | 15,191 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $83,313,000 | 5.12% |
| Defender Capital, LLC. | 4,997,870 | $12,245,000 | 3.92% |
| Raffles Associates | 543,590 | $1,332,000 | 1.28% |
| Prescott General Partners LLC | 1,851,851 | $4,537,000 | 0.16% |
| DCF Advisers, LLC | 85,000 | $208,000 | 0.08% |
| Long Focus Capital Management, LLC | 215,000 | $527,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $110,000 | 0.06% |
| DAFNA Capital Management LLC | 80,000 | $196,000 | 0.05% |
| Strategic Wealth Investment Group, LLC | 65,069 | $159,000 | 0.04% |
| Fort Sheridan Advisors LLC | 52,931 | $130,000 | 0.04% |